I cannot believe the lack of conversation on Freetrade regarding Avacta.
“A paradigm shift” for cancer treatment.
Wakey wakey
DYOR
3 Likes
If you ask pretty much any clinical professional if they’ve heard of Avacta - especially in UK, or their doxorubicin alternative, and the answer will likely be ‘no’. I think once cohort 7 is complete (most likely December), they’ll release trial data from p1a showing safety and signs of efficacy for peer review in early 24. Most likely coincide with mainstream media news coverage.
By end of 2025, it’s likely that Ava6000 will displace dox as first line treatment for STS in America, the fda will not allow do to be used once there is a safer and more effective alternative
I think if a major pharma wants the whole platform to improve their existing pipeline of drugs, eg £3bn which is criminally cheap, they’ll need to start making moves before then. Once the platform starts getting licence deals, partnerships, EUA for breast cancer or ovarian cancer, they’ll need to find £30bn+
Al wants to turn us in to the next Roche, if he can fight off hostile bids over next decade he just might do it.
2 Likes
Down 9% after the company released data from an early stafe study for AVA6000
Is there any chance of the share going high ? Facing huge loss at the moment